A study presented at ESTRO 2026 suggests prostate cancer radiotherapy could be delivered in only two sessions over eight days without adding side effects versus the conventional five-fraction schedule. The findings, reported in Stockholm, frame a potential de-escalation pathway focused on maintaining safety while reducing treatment time. For patients and providers, fewer visits can reduce burden and improve throughput in radiation oncology services. For industry stakeholders, regimen simplification can influence payer coverage discussions and operational models for departments delivering radiotherapy. The excerpt does not include absolute efficacy numbers or subgroup breakdowns, but the equal safety premise is the central takeaway from the presentation.